Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

Journal of Neurology

Issue Special Issue 2/2000

Content (18 Articles)

Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease

D. J. Brooks

Non-dopaminergic therapy in Parkinson’s disease

Horst Przuntek

Pathoanatomy of Parkinson’s disease

H. Braak, E. Braak

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

T. N. Chase, J. D. Oh, S. Konitsiotis

Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments

Peter Jenner

The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease

Olivier Rascol

Glial cells and Parkinson’s disease

E. C. Hirsch

Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease

H. Reichmann, B. Janetzky

Genetic influence on the development of Parkinson’s disease

O. Riess, W. Kuhn, R. Krüger

Projections from basal ganglia to tegmentum: a subcortical route for explaining the pathophysiology of Parkinson’s disease signs?

P. J. Delwaide, J.-L. Pepin, V. De Pasqua, A. M. de Noordhout

Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease

P. Foley, P. Riederer

Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson’s disease

A. Plaitakis, P. Shashidharan

MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies

E. Grünblatt, S. Mandel, M. B. H. Youdim

Preclinical (premotor) Parkinson’s disease

E. Ch. Wolters, C. Francot, P. Bergmans, A. Winogrodzka, J. Booij, H. W. Berendse, J. C. Stoof

Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET

A. Laihinen, H. Ruottinen, J. O. Rinne, M. Haaparanta, J. Bergman, O. Solin, M. Koskenvuo, R. Marttila, U. K. Rinne

Cognition and emotion in different stages and subtypes of Parkinson’s disease

F. Stocchi, L. Brusa

Thalamic, pallidal, or subthalamic surgery for Parkinson’s disease?

P. Krack, M. Poepping, D. Weinert, B. Schrader, G. Deuschl

Levodopa – an exotoxin or a therapeutic drug?

E. Melamed, D. Offen, A. Shirvan, I. Ziv

Mar 00
Issue: 3/2000
Apr 00
Issue: 4/2000

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more